By Kelly Cloonan
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
The stock rose 7% to $2.99 on Friday. Shares have lost 1% over the past 12 months.
The biopharmaceutical company said Thursday that the European Patent Office has confirmed the validity of its amended patent for split poly-A tail technology, which improves expression of the protein encoded on an mRNA construct to enhance the efficacy of certain vaccines.
BioNTech first filed a lawsuit regarding the patent in 2023.
After Thursday's ruling, the Regional Court Düsseldorf will decide if the amended patent has been infringed in a hearing scheduled for July 1.
"Today's decision marks an important step on our path that we expect will lead to recognition of CureVac's major contribution to safe and efficacious Covid-19 vaccines as the earliest pioneer in mRNA technology," said CureVac Chief Executive Dr. Alexander Zehnder.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
March 28, 2025 12:45 ET (16:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。